Close

Everest Medicines Begins Ops at mRNA Vaccine Production Site in China

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, began the first phase of operations at its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang Province.

The first phase of the project, covering an area of 58,000 square meters and with an investment of more than RMB 900 million, has a set of advanced production facilities built to meet global and China GMP standards, and designed with an annual production capacity of 700 million doses of mRNA vaccines.

In September 2021, Everest Medicines entered a strategic agreement with Providence Therapeutics Holdings Inc. to advance mRNA vaccines and therapies. Everest has since made progress, including industrial scale technology transfer of its mRNA platform, localized processing and analytical testing, and direct procurement with raw material suppliers, which will enable the company to independently develop and produce mRNA vaccines and innovative drugs. In a head-to-head Phase II clinical study conducted by Providence, its monovalent COVID-19 vaccine candidate PTX-COVID19-B was statistically non-inferior to Pfizer/BioNTech’s Comirnaty in terms of safety and efficacy.

Everest is developing an Omicron-based bivalent booster candidate, EVER-COVID19-M1.2, and plans to initiate clinical trials in China and other Everest territories next year. In addition, it will also develop other preventive and therapeutic vaccines against important infectious diseases and cancers by utilizing the technology platform. Among these, its mRNA rabies vaccine program has achieved preclinical proof-of-concept.

Latest stories

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back